AstraZeneca's (AZN) Hold Rating Reaffirmed at Deutsche Bank Aktiengesellschaft

Key Points

• Deutsche Bank reaffirmed its “hold” rating on AstraZeneca and maintained a £117 price target, implying approximately 6% downside from the prior close.
• Analyst sentiment remains broadly positive: six analysts rate the stock a Buy and one rates it Hold, producing a consensus “Moderate Buy” rating and an average target price of £150.
• AstraZeneca shares traded at £124.48, while insider Michel Demare purchased 2,500 shares at an average price of £121.21; insiders own 0.15% of the company.

AstraZeneca (LON:AZN - Get Free Report)'s stock had its "hold" rating reiterated by equities researchers at Deutsche Bank Aktiengesellschaft in a research report issued on Tuesday, Digital Look reports. They currently have a £117 price objective on the biopharmaceutical company's stock. Deutsche Bank Aktiengesellschaft's price objective would suggest a potential downside of 6.01% from the company's previous close.

A number of other brokerages have also recently weighed in on AZN. Citigroup increased their target price on shares of AstraZeneca from £175 to £178 and gave the stock a "buy" rating in a report on Tuesday, July 28th. Jefferies Financial Group reaffirmed a "buy" rating and set a £175 target price on shares of AstraZeneca in a research note on Wednesday, September 9th. Berenberg Bank reduced their price objective on AstraZeneca from £160 to £150 and set a "buy" rating for the company in a research report on Tuesday, September 15th. Finally, Royal Bank Of Canada reiterated an "outperform" rating and set a £145 price target on shares of AstraZeneca in a report on Tuesday, September 8th. Six investment analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company's stock. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of £150.

AstraZeneca Price Performance

Shares of AZN traded down GBX 44 during trading hours on Tuesday, reaching £124.48. The company had a trading volume of 27,813,750 shares, compared to its average volume of 30,410,363. AstraZeneca has a 12-month low of £109.22 and a 12-month high of £157.32. The company has a current ratio of 0.89, a quick ratio of 0.59 and a debt-to-equity ratio of 64.10. The firm has a 50 day simple moving average of £121.73 and a 200-day simple moving average of £133.31. The company has a market capitalization of £193.06 billion, a price-to-earnings ratio of 18.63, a PEG ratio of 0.86 and a beta of 0.20.

Insider Transactions at AstraZeneca

In other news, insider Michel Demare acquired 2,500 shares of the firm's stock in a transaction dated Monday, September 14th. The stock was bought at an average price of £121.21 per share, with a total value of £303,025. Insiders own 0.15% of the company's stock.

About AstraZeneca

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.